242 related articles for article (PubMed ID: 19826974)
21. HLA associations with infliximab-induced liver injury.
Bruno CD; Fremd B; Church RJ; Daly AK; Aithal GP; Björnsson ES; Larrey D; Watkins PB; Chow CR
Pharmacogenomics J; 2020 Oct; 20(5):681-686. PubMed ID: 32024945
[TBL] [Abstract][Full Text] [Related]
22. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology.
Grove JI; Aithal GP
Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):395-409. PubMed ID: 25491399
[TBL] [Abstract][Full Text] [Related]
23. The association between the NAT2 genetic polymorphisms and risk of DILI during anti-TB treatment: a systematic review and meta-analysis.
Zhang M; Wang S; Wilffert B; Tong R; van Soolingen D; van den Hof S; Alffenaar JW
Br J Clin Pharmacol; 2018 Dec; 84(12):2747-2760. PubMed ID: 30047605
[TBL] [Abstract][Full Text] [Related]
24. Comprehensive genome-wide evaluation of lapatinib-induced liver injury yields a single genetic signal centered on known risk allele HLA-DRB1*07:01.
Parham LR; Briley LP; Li L; Shen J; Newcombe PJ; King KS; Slater AJ; Dilthey A; Iqbal Z; McVean G; Cox CJ; Nelson MR; Spraggs CF
Pharmacogenomics J; 2016 Apr; 16(2):180-5. PubMed ID: 25987243
[TBL] [Abstract][Full Text] [Related]
25. Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA-Update with genetic correlations.
Bonkovsky HL; Ghabril M; Nicoletti P; Dellinger A; Fontana RJ; Barnhart H; Gu J; Daly AK; Aithal GP; Phillips EJ; Kleiner DE;
Liver Int; 2024 Jun; 44(6):1409-1421. PubMed ID: 38451034
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms of N-acetyltransferase 2 & susceptibility to antituberculosis drug-induced hepatotoxicity.
Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M
Indian J Med Res; 2016 Dec; 144(6):924-928. PubMed ID: 28474630
[TBL] [Abstract][Full Text] [Related]
27. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease.
Andrade RJ; Lucena MI; Alonso A; García-Cortes M; García-Ruiz E; Benitez R; Fernández MC; Pelaez G; Romero M; Corpas R; Durán JA; Jiménez M; Rodrigo L; Nogueras F; Martín-Vivaldi R; Navarro JM; Salmerón J; de la Cuesta FS; Hidalgo R
Hepatology; 2004 Jun; 39(6):1603-12. PubMed ID: 15185301
[TBL] [Abstract][Full Text] [Related]
28. Genetic basis of drug-induced liver injury: present and future.
Urban TJ; Daly AK; Aithal GP
Semin Liver Dis; 2014 May; 34(2):123-33. PubMed ID: 24879978
[TBL] [Abstract][Full Text] [Related]
29. Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens.
Nicoletti P; Devarbhavi H; Goel A; Venkatesan R; Eapen CE; Grove JI; Zafer S; Bjornsson E; Lucena MI; Andrade RJ; Pirmohamed M; Wadelius M; Larrey D; Maitland-van der Zee AH; Ibanez L; Watkins PB; Daly AK; Aithal GP
Clin Pharmacol Ther; 2021 Apr; 109(4):1125-1135. PubMed ID: 33135175
[TBL] [Abstract][Full Text] [Related]
30. T cells infiltrate the liver and kill hepatocytes in HLA-B(∗)57:01-associated floxacillin-induced liver injury.
Wuillemin N; Terracciano L; Beltraminelli H; Schlapbach C; Fontana S; Krähenbühl S; Pichler WJ; Yerly D
Am J Pathol; 2014 Jun; 184(6):1677-82. PubMed ID: 24731753
[TBL] [Abstract][Full Text] [Related]
31. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.
Cirulli ET; Nicoletti P; Abramson K; Andrade RJ; Bjornsson ES; Chalasani N; Fontana RJ; Hallberg P; Li YJ; Lucena MI; Long N; Molokhia M; Nelson MR; Odin JA; Pirmohamed M; Rafnar T; Serrano J; Stefánsson K; Stolz A; Daly AK; Aithal GP; Watkins PB; ;
Gastroenterology; 2019 May; 156(6):1707-1716.e2. PubMed ID: 30664875
[TBL] [Abstract][Full Text] [Related]
32. Single-nucleotide polymorphisms of
Yang WN; Pang LL; Zhou JY; Qiu YW; Miao L; Wang SY; Liu XZ; Tan KA; Shi WW; Wang GQ; Hou FQ
World J Gastroenterol; 2020 Mar; 26(12):1329-1339. PubMed ID: 32256020
[TBL] [Abstract][Full Text] [Related]
33. Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav.
Alshabeeb MA; Aithal GP; Daly AK
DNA Cell Biol; 2020 Mar; 39(3):349-354. PubMed ID: 31905014
[TBL] [Abstract][Full Text] [Related]
34. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.
Urban TJ; Shen Y; Stolz A; Chalasani N; Fontana RJ; Rochon J; Ge D; Shianna KV; Daly AK; Lucena MI; Nelson MR; Molokhia M; Aithal GP; Floratos A; Pe'er I; Serrano J; Bonkovsky H; Davern TJ; Lee WM; Navarro VJ; Talwalkar JA; Goldstein DB; Watkins PB; ; ; ; ;
Pharmacogenet Genomics; 2012 Nov; 22(11):784-95. PubMed ID: 22968431
[TBL] [Abstract][Full Text] [Related]
35. Estimating heritability of drug-induced liver injury from common variants and implications for future study designs.
Overby CL; Hripcsak G; Shen Y
Sci Rep; 2014 Jul; 4():5762. PubMed ID: 25042059
[TBL] [Abstract][Full Text] [Related]
36. Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?
Urban TJ; Goldstein DB; Watkins PB
Pharmacogenomics; 2012 May; 13(7):735-8. PubMed ID: 22594502
[TBL] [Abstract][Full Text] [Related]
37. Genetic risk factors in the development of idiosyncratic drug-induced liver injury.
Stephens C; Lucena MI; Andrade RJ
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):153-169. PubMed ID: 33222552
[No Abstract] [Full Text] [Related]
38. Antituberculous drug-induced liver injury: current perspective.
Devarbhavi H
Trop Gastroenterol; 2011; 32(3):167-74. PubMed ID: 22332331
[TBL] [Abstract][Full Text] [Related]
39. Drug-induced liver injury: insights from genetic studies.
Andrade RJ; Robles M; Ulzurrun E; Lucena MI
Pharmacogenomics; 2009 Sep; 10(9):1467-87. PubMed ID: 19761370
[TBL] [Abstract][Full Text] [Related]
40. Low N-acetyltransferase 2 activity in isoniazid-associated acute hepatitis requiring liver transplantation.
Cramer JP; Lohse AW; Burchard GD; Fischer L; Nashan B; Zimmermann M; Marx A; Kluge S
Transpl Int; 2010 Feb; 23(2):231-3. PubMed ID: 19686464
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
